Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

被引：1
|
作者：
Mienko, Fiona [1 ]
Halmos, Balazs [1 ]
Cheng, Haiying [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 12期
关键词：
PERFORMANCE STATUS; NIVOLUMAB; DOCETAXEL; EFFICACY;
D O I：
10.21037/atm.2020.02.68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [22] PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
    Miyawaki, Eriko
    Murakami, Haruyasu
    Mori, Keita
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (05) : 617 - 622
  • [23] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Kerr, Keith M.
    Nicolson, Marianne C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
  • [24] Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
    Sakamoto, Mandy
    Jimeno, Antonio
    DRUGS OF TODAY, 2023, 59 (03) : 169 - 177
  • [25] Advanced non-small cell lung cancer - treatment with Pembrolizumab
    Silvinato, Antonio
    Floriano, Idevaldo
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (03): : 256 - 256
  • [26] Advanced non-small cell lung cancer - Treatment with Pembrolizumab
    Silvinato, Antonio
    Floriono, Idevaldo
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (12): : 1423 - 1432
  • [27] Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
    Nhung Pham
    Quyet Do
    Thang Ta
    Dung Nguyen
    Dai Do
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [28] Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
    Shiotsu, Shinsuke
    Yoshimura, Akihiro
    Yamada, Tadaaki
    Morimoto, Kenji
    Tsuchiya, Michiko
    Yoshioka, Hiroshige
    Hiranuma, Osamu
    Chihara, Yusuke
    Yamada, Takahiro
    Hasegawa, Isao
    Ohta, Takahiro
    Takeda, Takayuki
    Hiraoka, Noriya
    Takayama, Koichi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [30] PD-L1 Expression and Response to Pembrolizumab in Japanese Patients with EGFR-Mutant Non-small Cell Lung Cancer
    Miyawaki, Eriko
    Murakami, Haruyasu
    Miyawaki, Taichi
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    ANNALS OF ONCOLOGY, 2019, 30
12345